Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of VA Combined With PD-1 Inhibitor in the Treatment of Relapsed and Refractory AML and High-risk MDS

NCT06536959 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT06536959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06536959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of VA Combined With PD-1 Inhibitor in the Treatment of Relapsed and Refractory AML and High-risk MDS
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 18, 2024
Completion date
July 31, 2027
Enrollment
67 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

minimal residual disease, myelodysplastic syndromes, refractory acute myeloid leukemia, relapsed acute myeloid leukemia